Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study
Open Access
- 6 April 2020
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 79 (6), 829-836
- https://doi.org/10.1136/annrheumdis-2020-217176
Abstract
Objectives To evaluate the associations of regular glucosamine use with all-cause and cause-specific mortality in a large prospective cohort. Methods This population-based prospective cohort study included 495 077 women and men (mean (SD) age, 56.6 (8.1) years) from the UK Biobank study. Participants were recruited from 2006 to 2010 and were followed up through 2018. We evaluated all-cause mortality and mortality due to cardiovascular disease (CVD), cancer, respiratory and digestive disease. HRs and 95% CIs for all-cause and cause-specific mortality were calculated using Cox proportional hazards models with adjustment for potential confounding variables. Results At baseline, 19.1% of the participants reported regular use of glucosamine supplements. During a median follow-up of 8.9 years (IQR 8.3-9.7 years), 19 882 all-cause deaths were recorded, including 3802 CVD deaths, 8090 cancer deaths, 3380 respiratory disease deaths and 1061 digestive disease deaths. In multivariable adjusted analyses, the HRs associated with glucosamine use were 0.85 (95% CI 0.82 to 0.89) for all-cause mortality, 0.82 (95% CI 0.74 to 0.90) for CVD mortality, 0.94 (95% CI 0.88 to 0.99) for cancer mortality, 0.73 (95% CI 0.66 to 0.81) for respiratory mortality and 0.74 (95% CI 0.62 to 0.90) for digestive mortality. The inverse associations of glucosamine use with all-cause mortality seemed to be somewhat stronger among current than non-current smokers (p for interaction=0.00080). Conclusions Regular glucosamine supplementation was associated with lower mortality due to all causes, cancer, CVD, respiratory and digestive diseases.Funding Information
- The National Natural Science Foundation of China (81973109)
- the national key Research and Development Program of China (2018YFC2000400)
- the National Institutes of Health (NIH)/National Institute on Aging (NIA) of USA (P30-AG028716)
- the Construction of High-level University of Guangdong (G618339167, G619339521)
- the Project Supported by Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme
This publication has 40 references indexed in Scilit:
- Association Between Use of Specialty Dietary Supplements and C-Reactive Protein ConcentrationsAmerican Journal of Epidemiology, 2012
- Who Uses Glucosamine and Why? A Study of 266,848 Australians Aged 45 Years and OlderPLOS ONE, 2012
- Effect of Glucosamine on Pain-Related Disability in Patients With Chronic Low Back Pain and Degenerative Lumbar OsteoarthritisJAMA, 2010
- Immunity, Inflammation, and CancerCell, 2010
- Cancer-related inflammationNature, 2008
- Complementary and Alternative Medicine Use Among Adults and Children: United States, 2007National Health Statistics Reports, 2008
- Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee OsteoarthritisThe New England Journal of Medicine, 2006
- EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)Annals Of The Rheumatic Diseases, 2003
- Glucosamine inhibits IL-1β-induced NFκB activation in human osteoarthritic chondrocytesOsteoarthritis and Cartilage, 2003
- Anti-inflammatory activity of chondroitin sulfateOsteoarthritis and Cartilage, 1998